Appointment Compliance in Patients With Diabetic Macular Edema and Exudative Macular Degeneration. 2018

Michael E Jansen, and Chelsey J Krambeer, and Daniel S Kermany, and Jana N Waters, and Wayne Tie, and Sepehr Bahadorani, and Julia Singer, and Jordan M Comstock, and Kendall W Wannamaker, and Michael A Singer, and

The purpose of this study is to compare cancellation and no-show rates in patients with diabetic macular edema (DME) and exudative macular degeneration (wet AMD). An anonymous survey was sent to 1,726 retina specialists inquiring as to the number of appointments their patients with DME and wet AMD attended, cancelled, or did not show up for in 2014 and 2015. Data were obtained on 109,599 appointments. Patients with DME in the U.S. had a 1.591-times increased odds of cancelling or no-showing to their appointments than patients with wet AMD (P < .0001). Patients with DME in Europe had a 1.918-times increased odds of cancelling or no showing to their appointments than patients with wet AMD (P < .0001). Patients with DME in the U.S. and Europe cancelled and no-showed to their appointments significantly more often than patients with wet AMD. These findings can be taken into consideration when establishing treatment plans for patients with DME. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:186-190.].

UI MeSH Term Description Entries
D008269 Macular Edema Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90) Central Retinal Edema, Cystoid,Cystoid Macular Edema,Macular Edema, Cystoid,Cystoid Macular Dystrophy,Cystoid Macular Edema, Postoperative,Irvine-Gass Syndrome,Macular Dystrophy, Dominant Cystoid,Edema, Cystoid Macular,Edema, Macular,Irvine Gass Syndrome,Syndrome, Irvine-Gass
D008297 Male Males
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D003930 Diabetic Retinopathy Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION. Diabetic Retinopathies,Retinopathies, Diabetic,Retinopathy, Diabetic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001071 Appointments and Schedules The different methods of scheduling patient visits, appointment systems, individual or group appointments, waiting times, waiting lists for hospitals, walk-in clinics, etc. Patient Appointments,Patient Schedules,Schedules, Patient,Appointments,Schedules,Appointment,Appointment, Patient,Appointments, Patient,Patient Appointment,Patient Schedule,Schedule,Schedule, Patient,Schedules and Appointments
D014792 Visual Acuity Clarity or sharpness of OCULAR VISION or the ability of the eye to see fine details. Visual acuity depends on the functions of RETINA, neuronal transmission, and the interpretative ability of the brain. Normal visual acuity is expressed as 20/20 indicating that one can see at 20 feet what should normally be seen at that distance. Visual acuity can also be influenced by brightness, color, and contrast. Acuities, Visual,Acuity, Visual,Visual Acuities
D042461 Vascular Endothelial Growth Factor A The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced. Vascular Endothelial Growth Factor,Vascular Endothelial Growth Factor-A,GD-VEGF,Glioma-Derived Vascular Endothelial Cell Growth Factor,VEGF,VEGF-A,Vascular Permeability Factor,Vasculotropin,Glioma Derived Vascular Endothelial Cell Growth Factor,Permeability Factor, Vascular

Related Publications

Michael E Jansen, and Chelsey J Krambeer, and Daniel S Kermany, and Jana N Waters, and Wayne Tie, and Sepehr Bahadorani, and Julia Singer, and Jordan M Comstock, and Kendall W Wannamaker, and Michael A Singer, and
April 2021, Ophthalmic surgery, lasers & imaging retina,
Michael E Jansen, and Chelsey J Krambeer, and Daniel S Kermany, and Jana N Waters, and Wayne Tie, and Sepehr Bahadorani, and Julia Singer, and Jordan M Comstock, and Kendall W Wannamaker, and Michael A Singer, and
January 2007, Ophthalmic research,
Michael E Jansen, and Chelsey J Krambeer, and Daniel S Kermany, and Jana N Waters, and Wayne Tie, and Sepehr Bahadorani, and Julia Singer, and Jordan M Comstock, and Kendall W Wannamaker, and Michael A Singer, and
April 2007, Annals of the New York Academy of Sciences,
Michael E Jansen, and Chelsey J Krambeer, and Daniel S Kermany, and Jana N Waters, and Wayne Tie, and Sepehr Bahadorani, and Julia Singer, and Jordan M Comstock, and Kendall W Wannamaker, and Michael A Singer, and
October 2021, International ophthalmology clinics,
Michael E Jansen, and Chelsey J Krambeer, and Daniel S Kermany, and Jana N Waters, and Wayne Tie, and Sepehr Bahadorani, and Julia Singer, and Jordan M Comstock, and Kendall W Wannamaker, and Michael A Singer, and
January 2014, Retinal cases & brief reports,
Michael E Jansen, and Chelsey J Krambeer, and Daniel S Kermany, and Jana N Waters, and Wayne Tie, and Sepehr Bahadorani, and Julia Singer, and Jordan M Comstock, and Kendall W Wannamaker, and Michael A Singer, and
June 2020, Expert opinion on investigational drugs,
Michael E Jansen, and Chelsey J Krambeer, and Daniel S Kermany, and Jana N Waters, and Wayne Tie, and Sepehr Bahadorani, and Julia Singer, and Jordan M Comstock, and Kendall W Wannamaker, and Michael A Singer, and
July 2011, American journal of ophthalmology,
Michael E Jansen, and Chelsey J Krambeer, and Daniel S Kermany, and Jana N Waters, and Wayne Tie, and Sepehr Bahadorani, and Julia Singer, and Jordan M Comstock, and Kendall W Wannamaker, and Michael A Singer, and
January 1988, Retina (Philadelphia, Pa.),
Michael E Jansen, and Chelsey J Krambeer, and Daniel S Kermany, and Jana N Waters, and Wayne Tie, and Sepehr Bahadorani, and Julia Singer, and Jordan M Comstock, and Kendall W Wannamaker, and Michael A Singer, and
July 2007, American journal of ophthalmology,
Michael E Jansen, and Chelsey J Krambeer, and Daniel S Kermany, and Jana N Waters, and Wayne Tie, and Sepehr Bahadorani, and Julia Singer, and Jordan M Comstock, and Kendall W Wannamaker, and Michael A Singer, and
March 2022, The Medical letter on drugs and therapeutics,
Copied contents to your clipboard!